AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1604411 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral administration of CN-100 at a dose of 300 mg
Number of subjects: 12
Study 1604411 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive oral administration of CN-100 at a daily dose of 300 mg
Number of subjects: 12
Study 1604411 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive oral administration of CN-100
Number of subjects: 12
Study 3728891 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine 2 mg i.v. prior to extubation
Number of subjects: 62
Study 3728891 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physostigmine)
Number of subjects: 62
Study 3728891 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine in patients younger than 60 years
Number of subjects: 62
Study 3728891 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine in sexagenarians (patients aged 60 years and older)
Number of subjects: 62
Study 29240641 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose insulin injections
Number of subjects: 91
Study 29240641 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 91
Study 26129928 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant group (500 mg of vitamin C and 117.5 mg vitamin E before and after training)
Number of subjects: 34
Study 26129928 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 34
Study 26129928 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant group
Number of subjects: 34
Study 26129928 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 23995581 — intervention group
Group type: EXPERIMENTAL
Intervention: tyrosine-phenylalanine depletion (TPD) beverage
Number of subjects: 16
Study 23995581 — intervention group
Group type: COMPARATOR
Intervention: tyrosine-phenylalanine balanced (BAL) control beverage
Number of subjects: 16
Study 22867101 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-method cooling
Number of subjects: 8
Study 20156396 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective messages (N=31) - 1 SMS per day for 2 weeks
Number of subjects: 120
Study 20156396 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental messages (N=30) - 1 SMS per day for 2 weeks
Number of subjects: 120
Study 20156396 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined messages (N=31) - 1 SMS per day for 2 weeks
Number of subjects: 120
Study 20156396 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=28) - 1 SMS per week
Number of subjects: 120
Study 18564096 — intervention group
Group type: EXPERIMENTAL
Intervention: Erroneous examples with elaborated feedback
Number of subjects: 153
Study 18564096 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of correct result (KCR)
Number of subjects: 153
Study 18564096 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 153
Study 15858471 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment
Number of subjects: 1065
Study 15858471 — intervention group
Group type: COMPARATOR
Intervention: Pimecrolimus cream
Number of subjects: 1065
Study 12393113 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine 4.3 microg.kg(‐1) plus IV 0.9% saline (Group 1)
Number of subjects: 45
Study 12393113 — intervention group
Group type: EXPERIMENTAL
Intervention: IV buprenorphine 1.3 microg.kg(‐1) plus intrathecal saline (Group 2)
Number of subjects: 45
Study 12393113 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 4.3 microg.kg(‐1) plus IV buprenorphine 1.3 microg.kg(‐1) (Group 3)
Number of subjects: 45
Study 10207203 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of basic fibroblast growth factor (bFGF) within hours after the onset of ischemia
Number of subjects: 0
Study 10207203 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracisternal administration of basic fibroblast growth factor (bFGF) starting at one day after ischemia
Number of subjects: 0
Study 10207203 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed administration of basic fibroblast growth factor (bFGF) as a recovery-promoting agent in subacute stroke
Number of subjects: 0
Study 7553405 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg once daily
Number of subjects: 75
Study 7553405 — intervention group
Group type: COMPARATOR
Intervention: Captopril 25 mg three times daily
Number of subjects: 75
Study 7553405 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg daily (one-year open treatment)
Number of subjects: 75
Study 2166758 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated EARs
Number of subjects: 18
Study 2166758 — intervention group
Group type: EXPERIMENTAL
Intervention: Early responses preceding LARs
Number of subjects: 18
Study 2166758 — intervention group
Group type: COMPARATOR
Intervention: Baseline levels in isolated responders
Number of subjects: 18
Study 2166758 — intervention group
Group type: COMPARATOR
Intervention: Baseline levels in dual responders
Number of subjects: 18
Study 2166758 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of bronchoconstriction during EAR
Number of subjects: 18
Study 2166758 — intervention group
Group type: COMPARATOR
Intervention: LAR
Number of subjects: 18
Study 373489 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupranolol (Ophtorenin) 0.05%
Number of subjects: 0
Study 373489 — intervention group
Group type: COMPARATOR
Intervention: Methazolamide (Neptazane) 50 mg p.o.
Number of subjects: 0
Study 373489 — intervention group
Group type: EXPERIMENTAL
Intervention: Methazolamide (Neptazane) 100 mg p.o.
Number of subjects: 0
Study 373489 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined application of Bupranolol and Methazolamide
Number of subjects: 0
Study 7114587 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (500 mg)
Number of subjects: 12
Study 7114587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31146741 — intervention group
Group type: EXPERIMENTAL
Intervention: NS-21 cream applied three times per day during RT or CCRT
Number of subjects: 30
Study 31146741 — intervention group
Group type: COMPARATOR
Intervention: Control treatment applied three times per day during RT or CCRT
Number of subjects: 30
Study 31146741 — intervention group
Group type: EXPERIMENTAL
Intervention: NS-21 cream
Number of subjects: 30
Study 31146741 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 30
Study 29300287 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramide-infused ostomy skin barrier
Number of subjects: 153
Study 27241125 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral Adipose Tissue (VAT)
Number of subjects: 97
Study 27241125 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Adipose Tissue (SAT)
Number of subjects: 97
Study 27241125 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 97
Study 27241125 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC)
Number of subjects: 97
Study 24935272 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) at a dose of 5 μg/kg subcutaneously every 12 hours for 5 consecutive days (group A)
Number of subjects: 46
Study 24935272 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard medical therapy (SMT) plus G-CSF (group A)
Number of subjects: 46
Study 24935272 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (SMT) alone (group B)
Number of subjects: 46
Study 22343498 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 μM
Number of subjects: 10
Study 22343498 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 50 μM
Number of subjects: 10
Study 22343498 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 75 μM
Number of subjects: 10
Study 22343498 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 5 μM
Number of subjects: 10
Study 22343498 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 20849244 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta (target 13.0-15.0 g/dL; Group 1)
Number of subjects: 291
Study 20849244 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta (target 10.5-11.5 g/dL; Group 2)
Number of subjects: 291
Study 20849244 — intervention group
Group type: COMPARATOR
Intervention: Epoetin beta (both groups)
Number of subjects: 291
Study 16716541 — intervention group
Group type: EXPERIMENTAL
Intervention: Rooming-in with mothers after delivery
Number of subjects: 176
Study 16716541 — intervention group
Group type: COMPARATOR
Intervention: Kept in the nursery after birth
Number of subjects: 176
Study 16716541 — intervention group
Group type: EXPERIMENTAL
Intervention: Swaddled babies with a 2-h separation period after birth
Number of subjects: 176
Study 16716541 — intervention group
Group type: COMPARATOR
Intervention: Swaddled babies kept in the nursery with breast-milk supplements
Number of subjects: 176
Study 16716541 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusively breastfed infants
Number of subjects: 176
Study 16716541 — intervention group
Group type: COMPARATOR
Intervention: Swaddled babies receiving supplements
Number of subjects: 176
Study 16224157 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil monotherapy
Number of subjects: 46
Study 16224157 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with ongoing lamivudine
Number of subjects: 46
Study 11916811 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgluteal approach
Number of subjects: 60
Study 11916811 — intervention group
Group type: COMPARATOR
Intervention: Popliteal approach
Number of subjects: 60
Study 11916811 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 60
Study 9483448 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 50 mg/kg administered intravenously just prior to IHCP (cimetidine group)
Number of subjects: 20
Study 9483448 — intervention group
Group type: COMPARATOR
Intervention: IHCP without cimetidine (control group)
Number of subjects: 20
Study 8536122 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiography ordered for acute knee injuries
Number of subjects: 3007
Study 8536122 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic series ordered
Number of subjects: 3007
Study 8536122 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' prediction of fracture
Number of subjects: 3007
Study 8536122 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' comfort level with not ordering radiography
Number of subjects: 3007
Study 8536122 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristics curve for physicians' prediction of fracture
Number of subjects: 3007
Study 8536122 — intervention group
Group type: EXPERIMENTAL
Intervention: Likelihood ratios for physicians' prediction of fracture
Number of subjects: 3007
Study 2237629 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior vertebral arthrodesis without instrumentation
Number of subjects: 48
Study 2237629 — intervention group
Group type: COMPARATOR
Intervention: Posterior vertebral arthrodesis with instrumentation (Harrington's technique)
Number of subjects: 48
Study 710028 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen alone (500 mg single oral dose)
Number of subjects: 6
Study 710028 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen with probenecid (500 mg 4 times a day)
Number of subjects: 6
Study 710028 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen with probenecid (250 mg twice daily for 8 days)
Number of subjects: 6
Study 710028 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen with probenecid
Number of subjects: 6
Study 31707266 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended Usual Care (R‐UC): 8 weeks of nicotine patch plus brief counseling
Number of subjects: 623
Study 31707266 — intervention group
Group type: COMPARATOR
Intervention: Abstinence‐Optimized Treatment (A‐OT): 3 weeks of pre‐quit mini‐lozenges, 26 weeks of nicotine patch plus mini‐lozenges, 11 counseling contacts, and 7‐11 automated reminders
Number of subjects: 623
Study 31707266 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment conditions
Number of subjects: 623
Study 27642037 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Intervention (EMI)
Number of subjects: 171
Study 27642037 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit and Vegetable Intervention (FVI)
Number of subjects: 171
Study 27642037 — intervention group
Group type: COMPARATOR
Intervention: Control (Diet-as-usual)
Number of subjects: 171
Study 25828193 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) exercise training, amplitude of 0.76 mm, frequency of 40Hz, peak acceleration of 23.9 m/s2, 5-week duration
Number of subjects: 19
Study 25828193 — intervention group
Group type: COMPARATOR
Intervention: Control group (statically mini-squatting position without WBV), 5-week duration
Number of subjects: 19
Study 24158333 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform switching (3.3-mm platform)
Number of subjects: 25
Study 24158333 — intervention group
Group type: COMPARATOR
Intervention: Standard implant (4-mm platform)
Number of subjects: 25
Study 21088595 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-down tilt position (15° head-down tilt)
Number of subjects: 40
Study 21088595 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 40
Study 21088595 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-down tilt position
Number of subjects: 40
Study 19875550 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced lifestyle advice
Number of subjects: 0
Study 19875550 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 17520787 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 33
Study 17520787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 15470213 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel every three weeks
Number of subjects: 1006
Study 15470213 — intervention group
Group type: COMPARATOR
Intervention: Weekly docetaxel
Number of subjects: 1006
Study 15470213 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 1006
Study 12813832 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended recruitment period
Number of subjects: 0
Study 12813832 — intervention group
Group type: EXPERIMENTAL
Intervention: Identified additional recruitment centres
Number of subjects: 0
Study 12813832 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced overall sample size
Number of subjects: 0
Study 9048709 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (20 mg IV monthly) and methylprednisolone (1 g IV monthly)
Number of subjects: 42
Study 9048709 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone alone
Number of subjects: 42
Study 7508727 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 68
Study 7508727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 3525022 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbutaline, 5 mg qid
Number of subjects: 13
Study 3525022 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline, 400 micrograms qid
Number of subjects: 13
Study 3525022 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical tablets or metered-dose inhalers)
Number of subjects: 13
Study 31286733 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (needles retained for 30 min, 3 times a day for 5 days)
Number of subjects: 120
Study 31286733 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment and care (Control group)
Number of subjects: 120
Study 28190788 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg kg−1 hour−1
Number of subjects: 24
Study 28190788 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg kg−1 hour−1
Number of subjects: 24
Study 26521582 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlong Xizhu acupuncture
Number of subjects: 60
Study 26521582 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 60
Study 23087258 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 29
Study 23087258 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupus health passport
Number of subjects: 29
Study 23087258 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life and mental health improvements
Number of subjects: 29
Study 21502549 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin (subcutaneous administration for 6 weeks: 2 weeks at therapeutic dose, 4 weeks at half therapeutic dose)
Number of subjects: 503
Study 21502549 — intervention group
Group type: COMPARATOR
Intervention: No nadroparin (control group)
Number of subjects: 503
Study 21502549 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin
Number of subjects: 503
Study 18704414 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete cementing (both under the baseplate and around the stem)
Number of subjects: 30
Study 18704414 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal cementing (only under the baseplate)
Number of subjects: 30
Study 16504957 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN (80 microg s.c. once a week for 24 weeks)
Number of subjects: 22
Study 16504957 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 22
Study 16504957 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN
Number of subjects: 22
Study 15575830 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacrimal occlusion with collagen plugs
Number of subjects: 14
Study 15575830 — intervention group
Group type: COMPARATOR
Intervention: Topical timolol (0.5%) without lacrimal occlusion
Number of subjects: 14
Study 11144316 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum (MS)
Number of subjects: 26
Study 11144316 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord (UC)
Number of subjects: 26
Study 11144316 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic fluid (AF)
Number of subjects: 26
Study 11144316 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant serum leptin concentrations (N5)
Number of subjects: 26
Study 11144316 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 26
Study 9072665 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulating drug of bacterial derivation
Number of subjects: 0
Study 1476466 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine infusion regimen (8 mg of quinine base/kg of body weight over 1 h followed by 8 mg of base/kg over 7 h, then 8 mg/kg over 8 h 3 times daily for 3 days)
Number of subjects: 20
Study 1476466 — intervention group
Group type: COMPARATOR
Intervention: Classical regimen (8 mg of base/kg over 8 h, 3 times daily for 3 days)
Number of subjects: 20
Study 6439759 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral digoxin, 0.5 mg daily, on days 10 through 22 of a menstrual cycle
Number of subjects: 0
Study 6439759 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous digoxin, 0.5 mg daily for days 7 through 21 of a menstrual cycle
Number of subjects: 0
Study 6439759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30820517 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine-High (CR-H; 0.3 g/kg/day of creatine + 0.1 g/kg/day of maltodextrin)
Number of subjects: 33
Study 30820517 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine-Moderate (CR-M; 0.1 g/kg/day of creatine + 0.3 g/kg/day of maltodextrin)
Number of subjects: 33
Study 30820517 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA; 0.4 g/kg/day of maltodextrin)
Number of subjects: 33
Study 29898437 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil (5 mg)
Number of subjects: 418
Study 29898437 — intervention group
Group type: COMPARATOR
Intervention: heparin (5,000 IU)
Number of subjects: 418
Study 27509603 — intervention group
Group type: COMPARATOR
Intervention: Routine detumescence (control group)
Number of subjects: 120
Study 27509603 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint massage and mild moxibustion (observation group)
Number of subjects: 120
Study 25271826 — intervention group
Group type: EXPERIMENTAL
Intervention: Headphones playing investigator-selected music
Number of subjects: 34
Study 25271826 — intervention group
Group type: COMPARATOR
Intervention: Muted headphones
Number of subjects: 34
Study 22922034 — intervention group
Group type: EXPERIMENTAL
Intervention: 22% carbamide peroxide (CP) with 3% potassium nitrate
Number of subjects: 21
Study 20130407 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific diet based on IgG antibodies against food antigens
Number of subjects: 40
Study 20130407 — intervention group
Group type: COMPARATOR
Intervention: Sham diet
Number of subjects: 40
Study 20130407 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophil-derived neurotoxin measurement
Number of subjects: 40
Study 17919542 — intervention group
Group type: COMPARATOR
Intervention: Transdermal buprenorphine patch applied for 3 days
Number of subjects: 49
Study 17919542 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine patch applied for 4 days
Number of subjects: 49
Study 16122587 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner Violence Screen (PVS) with injury location
Number of subjects: 200
Study 16122587 — intervention group
Group type: EXPERIMENTAL
Intervention: short-Woman Abuse Screening Tool (short-WAST) with injury location
Number of subjects: 200
Study 12697080 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 1558
Study 12697080 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Number of subjects: 1558
Study 10657535 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH test during cocaine withdrawal
Number of subjects: 26
Study 10657535 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH test after 30 days of cocaine abstinence
Number of subjects: 26
Study 8527287 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone (10-800 mg)
Number of subjects: 42
Study 8527287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 1453728 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (PP)
Number of subjects: 100